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Chemokine Receptors in Melanoma: CCR9 Has a Potential Role in
Metastasis to the Small Bowel
As with most cancers, the primary lesions of melanoma do
not kill patients. Rather, the metastases that appear in the
brain, liver, lung, and other sites are the leading causes of
morbidity and mortality in patients. Whereas clinicians have
long known that certain cancers tend to metastasize to
certain organs, the molecular factors that regulate organ-
selective metastasis are poorly understood.
Seminal work by Zlotnik and colleagues (Mu¨ller et al,
2001) suggested that specific chemokine receptors (Rossi
and Zlotnik, 2000), families of related G-protein-coupled,
seven-transmembrane spanning cell surface receptors, and
their ligands (chemokines) could be involved in organ-
selective tumor metastasis. Mu¨ller et al, as well as our own
group (Murakami et al, 2002), demonstrated that a limited
number of chemokine receptors are expressed by cancer
cell lines and that CXCR4 facilitates lung and lymph node
metastasis of breast cancer and melanoma cells. Other
reports suggested that expression of CCR7 (Wiley et al,
2001; Mashino et al, 2002) by various forms of cancer may
enhance lymph node metastasis and that CCR10 may
facilitate tumor progression in the skin (Murakami et al,
2003). In all these cases, the chemokine ligand that binds to
each of the three receptors above is expressed at high levels
in the specific tissues where metastases frequently occur.
Melanoma also metastasizes frequently to the gastro-
intestinal tract. Indeed, up to 60% of patients show
evidence of gastrointestinal metastases at autopsy (Blecker
et al, 1999). Nearly 50% of these metastases are in the small
bowel, but others appear in the colon or anorectum. In this
issue of the JID, Letsch et al (2004) examine the role of
CCR9 in melanoma metastases to the small bowel. They
explored this possibility because the CCR9 ligand, CCL25
(TECK), was previously shown to be selectively and
constitutively expressed in the epithelium of the small
bowel and thymus (Wurbel et al, 2000), and thus represents
a potential ‘‘attractive force’’ for melanoma cells that
express CCR9. Letsch et al found that eight of 20 melanoma
cell lines showed functional CCR9 expression. Interestingly,
three of the CCR9-positive cell lines were derived from
resections of small bowel metastases, and one line
(established from a nodal metastasis) was obtained from a
patient who eventually developed a small bowel metastasis.
Letch et al also demonstrated that metastatic melanoma
cells isolated immediately following resection of a small
bowel metastasis showed CCR9 expression, suggesting
that the expression of CCR9 was present in vivo at the site
of metastasis.
Why do melanoma cells and other cancer cells express
chemokine receptors? Whereas chemokine receptors have
traditionally been recognized for their ability to stimulate
directional migration (or ‘‘chemotaxis’’) of cells, other
functions of these receptors may be critical in their ability
to regulate organ-selective metastasis. Recent evidence
suggests that CCR10 may enable melanoma cells to elude
immune attack by activation of the prosurvival kinase Akt
(Murakami et al, 2003). Other receptors, including CXCR4,
may increase the ability of cancer cells to arrest on blood
vessels that express CXCL12 (SDF-1) (Cardones et al,
2003), to alter migratory properties (Robledo et al, 2001), or
to enhance survival (Murakami et al, 2002).
The roles of CCR9/CCL25 (TECK) in small bowel
metastasis may be analogous to those of CCR10/CCL27
in progression of melanoma in the skin, perhaps promoting
retention of these cells in the environs of the small bowel
through prosurvival pathways. Of note, both CCL25 and
CCL27 show nearly exclusive expression in the skin and
gut, respectively. Moreover, skin-homing and gut-homing
populations of T cells express high levels of CCR10 and
CCR9, respectively, enabling them to home more effectively
to these important sites of immune surveillance (Homey
et al, 2002; Onai et al, 2002).
Plausible roles for chemokine receptors in organ-selec-
tive metastasis are emerging. Specific production or
localization of chemokines in various tissues increases the
potential for tumor cells bearing the appropriate receptor to
localize and, perhaps more importantly, to survive at these
sites. In several of the animal models described in the
reports above, blockade of chemokines or their receptors
led to impressive inhibition of experimental metastasis,
suggesting that antagonism of chemokine receptor path-
ways in cancer patients may be a novel and rational therapy
for reducing the devastating effects of metastasis in
patients with melanoma and other cancers.
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